@PECjournal We published a CUA of denosumab well after it was listed, because additional evidence was published post-listing and the price of the comparator dropped when it went off patent - https://t.co/xAFZoSi9uL
899 followers
2,181 followers
What are we paying for? Cost-effectiveness analysis of patented denosumab and generic alendronate https://t.co/fqAxYfytam
3,234 followers
Current price of #denosumab should be lowered >50 % to demonstrate cost-effectiveness to Australian community https://t.co/lPczx5twDZ
3,234 followers
Current price of #denosumab should be ↓ by >50 % to demonstrate cost-effectiveness to Australian community https://t.co/lPczx5twDZ